- Home
- PC vs VCNX Comparison
PC vs VCNX Comparison
Compare PC & VCNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PC
- VCNX
- Stock Information
- Founded
- PC 2012
- VCNX 2001
- Country
- PC Singapore
- VCNX United States
- Employees
- PC N/A
- VCNX N/A
- Industry
- PC Restaurants
- VCNX Biotechnology: Pharmaceutical Preparations
- Sector
- PC Consumer Discretionary
- VCNX Health Care
- Exchange
- PC Nasdaq
- VCNX Nasdaq
- Market Cap
- PC 11.1M
- VCNX 10.5M
- IPO Year
- PC 2024
- VCNX N/A
- Fundamental
- Price
- PC $0.78
- VCNX $1.41
- Analyst Decision
- PC
- VCNX
- Analyst Count
- PC 0
- VCNX 0
- Target Price
- PC N/A
- VCNX N/A
- AVG Volume (30 Days)
- PC 218.3K
- VCNX 96.1K
- Earning Date
- PC 12-24-2024
- VCNX 11-14-2024
- Dividend Yield
- PC N/A
- VCNX N/A
- EPS Growth
- PC N/A
- VCNX N/A
- EPS
- PC N/A
- VCNX N/A
- Revenue
- PC $3,809,288.00
- VCNX $388,000.00
- Revenue This Year
- PC N/A
- VCNX N/A
- Revenue Next Year
- PC N/A
- VCNX N/A
- P/E Ratio
- PC N/A
- VCNX N/A
- Revenue Growth
- PC N/A
- VCNX N/A
- 52 Week Low
- PC $0.60
- VCNX $1.25
- 52 Week High
- PC $5.73
- VCNX $13.02
- Technical
- Relative Strength Index (RSI)
- PC N/A
- VCNX 27.23
- Support Level
- PC N/A
- VCNX $3.34
- Resistance Level
- PC N/A
- VCNX $4.35
- Average True Range (ATR)
- PC 0.00
- VCNX 0.50
- MACD
- PC 0.00
- VCNX -0.19
- Stochastic Oscillator
- PC 0.00
- VCNX 4.87
About PC Premium Catering (Holdings) Limited Ordinary Shares
Premium Catering (Holdings) Ltd is a company that conducts its operations through its subsidiary is mainly engaged in food catering for functions, events, and workers in Singapore. They specialize in Indian, Bangladesh, and Chinese cuisine and all its food products are Halal food which is permissible for consumption by Muslims to consume.
About VCNX Vaccinex Inc.
Vaccinex Inc is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company's lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. The firm has also developed a proprietary drug discovery platform, ActivMAb.